Given the pathophysiological importance of the Sema4D–Plexin-B1 interaction in mouse models of osteoporosis and MS, a pharmacological intervention to block their interaction could represent a promising therapeutic approach to treat osteoporosis and MS. Here, SEMA4D is linked to myeloid sarcoma.